THE LEADING RNAi THERAPEUTICS COMPANY

Alnylam has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases in a different way - by silencing the genes that cause or contribute to them. We are working diligently to develop RNAi-based medicines to benefit as many patients as possible.

icon

About Alnylam

We are a biopharmaceutical company driven by science and committed to delivering transformational medicines for patients.

icon

Our Pipeline

Our robust pipeline of investigational RNAi therapeutics is focused on both rare and prevalent diseases in several therapeutic areas.

icon

Corporate 
Responsibility

We believe that Alnylam can have a positive impact on the world beyond the medicines we make and embrace the opportunity to be a force for good.

SILENCING GENES TO TREAT DISEASE

RNA interference (RNAi) is a naturally occurring process already at work inside your body which regulates how genes make new proteins. Proteins play a critical role in almost everything your body does, but sometimes, they can cause or contribute to disease. Our medicines leverage the RNAi process to selectively target and prevent specific proteins from being made, “silencing” gene expression to treat disease at its source.

JOIN US

Incredible things happen when science and culture come together, and we believe that our people are our greatest strength. Together, we have built an inclusive, exceptional workplace where everyone can do their best work. To those who say impossible, impractical, unrealistic, we say, Challenge Accepted.

ALNYLAM NEWS

For more news, visit our News Room or view our Press Releases.